Dyax Corp. · Cambridge, MA United States (NASDAQ: DYAX)
| 300 Technology Sq. | Phone: 617-225-2500 |
| Cambridge, MA | Fax: 617-225-2501 |
| 02139 | |
| United States | 
Map This Company |
Dyax Corp. Rankings
| Russell 2000 (June 2011) |
Company Description
Dyax is arming the war against disease. The biopharmaceutical company develops drugs from its proprietary technology that rapidly identifies proteins, peptides, and antibodies it can use to treat disease, with a primarily focus on oncology and inflammation remedies. Dyax's first commercial drug, Kalbitor (DX-88), has been approved in the US to treat hereditary angioedema (HAE, a condition causing tissue swelling) in patients 16 and older. DX-88 is being investigated for additional indications. The company has other product candidates in discovery and development stages, including drugs that inhibit cancerous tumor growth.
Dyax Corp. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: DYAX Single Location |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 120 |
Executives
48 executives listed for Dyax Corp.'s Cambridge, MA location.
| Chairman | Henry Blair | |
|---|---|---|
| President, CEO, and Director | Gustav Christensen | |
| EVP and CFO | George Migausky |